Gastro-oesophageal reflux disease: symptoms, erosions, and Barrett’s—what is the interplay?

The presence of Barrett’s oesophagus may exert a negative impact on healing of erosive oesophagitis in gastro-oesophageal reflux disease The outcomes of patients with erosive oesophagitis, treated with acid suppression therapy (proton pump inhibitors), has been dictated by the baseline severity of erosive oesophagitis, presence of hiatus hernia, duration of therapy and, in some studies, by the Helicobacter pylori status of the patients.1,2 It has been shown that higher grades of erosive oesophagitis (Los Angeles grades C and D) have significantly lower healing rates as opposed to those with lower grades of erosive oesophagitis (grades A and B). Moreover, the majority of the oesophagitis trials have evaluated healing at four and eight weeks, showing a higher proportion of patients with all grades of erosive oesophagitis healed at week 8 compared with week 4.3,4 Similar data on healing at >8 weeks are not consistently available in the literature. Not only do patients with severe grades of erosive oesophagitis have a higher degree of oesophageal acid exposure compared with those with either no oesophagitis or low grades of oesophagitis, but they also have low amplitude of oesophageal contractions and the presence of large hiatus hernias.5 Therefore, it is not surprising that the poor pathophysiology associated with severe erosive oesophagitis leads to poor healing rates. Although a few studies have correlated H pylori status with oesophagitis healing, with H pylori positivity associated with improved healing rates, this has not been consistently documented.6 This may be a phenomenon …

[1]  S. Kihara,et al.  Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn’s disease , 2005, Gut.

[2]  P. Malfertheiner,et al.  Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study , 2005, Gut.

[3]  P. Muller,et al.  Translocation of p21Cip1/WAF1 from the nucleus to the cytoplasm correlates with pancreatic myofibroblast to fibroblast cell conversion , 2005, Gut.

[4]  Y. Yamaji,et al.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study , 2005, Gut.

[5]  H. Ubukata,et al.  A case of untreated gastric cancer followed for 7 years. , 2004, Gastrointestinal endoscopy.

[6]  A. Masamune,et al.  A c-Jun NH2-Terminal Kinase Inhibitor SP600125 (Anthra[1,9-cd]pyrazole-6 (2H)-one) Blocks Activation of Pancreatic Stellate Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  A. Beaudet,et al.  Leukocyte migration in adipose tissue of mice null for ICAM-1 and Mac-1 adhesion receptors. , 2004, Obesity research.

[8]  R. Busse,et al.  From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. , 2004, Diabetes.

[9]  F. Pace,et al.  Gastroesophageal Reflux Disease: A Typical Spectrum Disease (A New Conceptual Framework is Not Needed) , 2004, American Journal of Gastroenterology.

[10]  M. Lazar,et al.  Inflamed about obesity , 2004, Nature Medicine.

[11]  M. Boscaro,et al.  Adipose Tissue as an Endocrine Organ? A Review of Recent Data Related to Cardiovascular Complications of Endocrine Dysfunctions , 2004, Clinical and experimental hypertension.

[12]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[13]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[14]  S. Kihara,et al.  Obesity, adiponectin and vascular inflammatory disease , 2003, Current opinion in lipidology.

[15]  J. Galmiche,et al.  Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. , 2003, Gastroenterologie clinique et biologique.

[16]  R. Henry,et al.  Adiponectin: more than just another fat cell hormone? , 2003, Diabetes care.

[17]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[18]  J. Virtamo,et al.  Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  D. Loskutoff,et al.  Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Mireille André,et al.  Preadipocyte Conversion to Macrophage , 2003, The Journal of Biological Chemistry.

[21]  Pedro Iglesias,et al.  The role of the novel adipocyte-derived hormone adiponectin in human disease. , 2003, European journal of endocrinology.

[22]  M. Taguchi,et al.  Oleic Acid-Induced Pancreatitis Alters Expression of Transforming Growth Factor-&bgr;1 and Extracellular Matrix Components in Rats , 2003, Pancreas.

[23]  J. Auwerx,et al.  Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases , 2002, The Lancet.

[24]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[25]  H. Yoshikawa,et al.  Cytoplasmic p21Cip1/WAF1 regulates neurite remodeling by inhibiting Rho-kinase activity , 2002, The Journal of cell biology.

[26]  A. Masamune,et al.  Alcohol activates activator protein-1 and mitogen-activated protein kinases in rat pancreatic stellate cells. , 2002, The Journal of pharmacology and experimental therapeutics.

[27]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[28]  G. Marinos,et al.  Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. , 2002, Liver.

[29]  M. Korsten,et al.  Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis , 2002, Gut.

[30]  D. Johnson,et al.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis , 2002, American Journal of Gastroenterology.

[31]  T. Yao [Inflammatory bowel diseases]. , 2002, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[32]  E. Furth,et al.  An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis , 2001, American Journal of Gastroenterology.

[33]  K. McColl,et al.  Helicobacter pylori and reflux disease , 2001, The Lancet.

[34]  P. Kahrilas,et al.  Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients , 2001, American Journal of Gastroenterology.

[35]  A. Helicobacter,et al.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts , 2001, Gut.

[36]  P. Moayyedi Dyspepsia: The Clinical Consequences. , 2001 .

[37]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Oshima,et al.  Natural history of early gastric cancer: a non-concurrent, long term, follow up study , 2000, Gut.

[39]  B. Staels,et al.  Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.

[40]  G. Falk,et al.  Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial , 2000, Alimentary pharmacology & therapeutics.

[41]  R. Ahima,et al.  Adipose Tissue as an Endocrine Organ , 2006, Obesity.

[42]  NoriyukiOuchi,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[43]  P. Pederzoli,et al.  Collagen type I synthesized by pancreatic periacinar stellate cells (PSC) co‐localizes with lipid peroxidation‐derived aldehydes in chronic alcoholic pancreatitis , 2000, The Journal of pathology.

[44]  D. Jewell,et al.  The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link , 2000, The Journal of pathology.

[45]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[46]  J S Wilson,et al.  Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. , 1999, The American journal of pathology.

[47]  J. Auwerx,et al.  Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. , 1999, Gastroenterology.

[48]  P. Malfertheiner,et al.  Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. , 1999, Gastroenterology.

[49]  S. Friedman,et al.  Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy , 1999, Journal of gastroenterology and hepatology.

[50]  K. Miyazono,et al.  Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation , 1999, The EMBO journal.

[51]  P. Malfertheiner,et al.  Role of aging in the expression of Helicobacter pylori gastritis in the antrum, corpus, and cardia. , 1999, Scandinavian journal of gastroenterology.

[52]  S. Coppack,et al.  Adipose tissue as an endocrine and paracrine organ , 1998, International Journal of Obesity.

[53]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[54]  R. Schmid,et al.  Identification, culture, and characterization of pancreatic stellate cells in rats and humans. , 1998, Gastroenterology.

[55]  R. Sampliner,et al.  Short segment Barrett's esophagus—the need for standardization of the definition and of endoscopic criteria , 1998, American Journal of Gastroenterology.

[56]  G. Griffioen,et al.  Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis? , 1998, American Journal of Gastroenterology.

[57]  M. Korsten,et al.  Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture , 1998, Gut.

[58]  J. Levine,et al.  Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. , 1998, The Journal of clinical investigation.

[59]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[60]  Philipp E. Scherer,et al.  The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor , 1998, Current Biology.

[61]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[62]  M. Fujimiya,et al.  Morphological and Immunocytochemical Identification of Periacinar Fibroblast‐like Cells Derived from Human Pancreatic Acini , 1997, Pancreas.

[63]  B. Spiegelman,et al.  Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.

[64]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[65]  B. Baxter,et al.  Transforming growth factor-beta 1 inhibits human arterial smooth-muscle cell proliferation in a growth-rate-dependent manner. , 1995, American journal of surgery.

[66]  A. Shar,et al.  Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. , 1995, Gastroenterology.

[67]  P. Nyström,et al.  Intraoperative enteroscopy in Crohn's disease , 1993, The British journal of surgery.

[68]  S. Friedman The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies , 1993 .

[69]  N. Shepherd,et al.  Fat‐wrapping in Crohn's disease: Pathological basis and relevance to surgical practice , 1992, The British journal of surgery.

[70]  R. Diegelmann,et al.  Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells. , 1990, Gastroenterology.

[71]  T. Ledin,et al.  The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. , 1989, Scandinavian journal of gastroenterology.

[72]  C. McConkey,et al.  Gastric cancer: A 25‐year review , 1989, The British journal of surgery.

[73]  J. Rotter,et al.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. , 1982, Gastroenterology.

[74]  G. Oppenheimer,et al.  Regional ileitis; a pathologic and clinical entity. , 1952, The American journal of medicine.

[75]  田中 啓之 Cytoplasmic p21Cip1/WAF1 regulates neurite remodeling by inhibiting Rho-kinase activity , 2005 .

[76]  A. Masamune,et al.  A c-Jun N-terminal Kinase Inhibitor SP600125 Blocks Activation of Pancreatic Stellate Cells , 2004 .

[77]  L. Pénicaud,et al.  Preadipocyte conversion to macrophage: evidence of plasticity , 2002 .

[78]  Cancer incidence in five continents. Volume VIII. , 2002, IARC scientific publications.

[79]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[80]  E. Furth,et al.  An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. , 2001, The American journal of gastroenterology.

[81]  A. Greenberg,et al.  The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes. , 1998, Molecular endocrinology.

[82]  S. Friedman Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. , 1993, The New England journal of medicine.

[83]  R. Uibo,et al.  Chronic gastritis: progression of inflammation and atrophy in a six-year endoscopic follow-up of a random sample of 142 Estonian urban subjects. , 1991, Scandinavian journal of gastroenterology. Supplement.